Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI Formulary Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Medicare Plus Blue Group PPO & Prescription Blue Group PDP 2026 Formulary (Drug List)

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the 2026 formulary (drug list) for Medicare Plus Blue Group PPO and Prescription Blue Group PDP and describes which prescription drugs the plans cover, member use instructions, and coverage rules such as prior authorization, quantity limits, step therapy, and exception processes for plan members and providers.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedicare Plus Blue Group PPO & Prescription Blue Group PDP 2026 Formulary (Drug List)
    Policy CodePolicy N/A
    Change TypeAnnual formulary update (no material changes)
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when the formulary Requirements/Limits field shows 'PA' to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    06/01/2026formulary effective/updated date
    31 daystemporary transition supply
    72/24 hrsexception decision timeframes
    QL / PA / ST / OVMrequirement codes
    NDS / QLopioid controls

    Formulary Coverage Rules and Product Listings

    Formulary coverage rules and member exception/transition protections

    Covered when ALL of the following member protections and operational rules are met:

    Formulary Coverage Basics: The plan generally covers drugs listed on the formulary when they are medically necessary, dispensed at a network pharmacy, and all applicable plan requirements are met.

    Source: formulary overview and restrictions (chunks 3,11).

    Mid‑year formulary changes: The plan may add/remove drugs, change tiers, or add restrictions during the year in accordance with Medicare rules. For immediate substitutions when a generic or certain biosimilar is added, changes may take effect immediately; for other changes the plan will provide at least 30 days' notice or allow a 31‑day refill at time of request.30 days / 31 days

    Source: mid‑year change rules and member notice (chunks 3,4).

    Temporary transition/emergency supply:
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedicare Plus Blue Group PPO & Prescription Blue Group PDP 2026 Formulary (Drug List)
    Policy CodePolicy N/A
    Change TypeAnnual formulary update (no material changes)
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when the formulary Requirements/Limits field shows 'PA' to avoid denial of coverage.
    SourceLink
    On This Page
    Formulary Coverage Rules and Product ListingsFormulary Codes, Flags and ExamplesAuthorization, Step Therapy, Documentation and Denial RisksStep Therapy Flags and Affected ProductsPer-Product Quantity Limits (Selected Examples)Abbreviations and Terms Used in the FormularyBackground Information
    If a member’s drug is not on the 2026 formulary or a new restriction is added, the plan will cover a temporary 31‑day supply while the member and prescriber pursue alternatives or an exception; special 31‑day transition supplies apply for long‑term care residents and during facility transitions.
    31 days

    Source: temporary transition supply policy (chunk 15).

    Exception request and timelines: Members or prescribers may request formulary or tiering exceptions and must provide a prescriber statement explaining medical necessity. Standard decisions are completed within 72 hours; expedited (24‑hour) decisions are available when waiting could cause serious harm.72 hours / 24 hours

    Source: exception process and decision timeframes (chunk 14).

    Formulary drug coverage entries

    Formulary entries are covered subject to the Drug Tier and any Requirements/Limits shown in the product row.

    Entry fields that determine coverage: Each formulary line includes a Drug Tier and a Requirements/Limits field (examples: QL, PA, NDS, ST, OVM). Coverage of a listed product is conditional on satisfying the flags shown in its Requirements/Limits field.

    Examples shown in formulary listings (chunks 25,29,31).

    Common Requirements/Limits examples: Examples of Requirements/Limits that affect coverage include: QL (quantity limits with exact allowed units/timeframe), PA (prior authorization required), NDS (non‑extended day supply controls), ST (step therapy), and OVM (Oncology Value Management).

    See per‑product entries for specific QL/PA/ST flags (chunks 25,29,31).

    Coverage rules inferred from formulary flags

    Interpret the Requirements/Limits flags on each product row as operational coverage rules:

    PA flag: If a product's Requirements/Limits includes 'PA', prior authorization is required before the drug will be covered. Prescribers must follow the plan's PA process and submit required clinical documentation.

    Many specialty and oncology agents list 'PA' (chunks 108–119, 114–117).

    OVM and oncology agents: If a product's Requirements/Limits includes 'OVM' (Oncology Value Management), the drug requires additional oncology verification/management through the plan's OVM process in addition to any PA requirements.

    Numerous antineoplastics and supportive care agents are listed with 'PA; OVM' (chunks 108–116).

    QL flag: If a product's Requirements/Limits includes 'QL(...)' the dispensed quantity and days' supply must not exceed the stated limit; claims beyond the QL may be denied unless an exception is approved.Per product QL as listed

    Examples of QL values are shown inline for many specialty and non‑specialty drugs (chunks 114,115,125).

    Formulary coverage by product

    Products listed on the formulary are covered when dispensed consistent with their listed tier and any Requirements/Limits.

    Tiered coverage: Each product row lists a Drug Tier (Tier 1–5) which determines cost‑sharing; coverage is provided per the tier shown when other requirements (PA, QL, ST, etc.) are satisfied.

    Tier assignments appear on product rows (chunks 162,181).

    Apply Requirements/Limits per product: For any product that includes Requirements/Limits (e.g., QL or PA), coverage is conditional on meeting those specific limits or obtaining required authorization before dispensing.

    See individual product entries for per‑product flags (chunks 162,181).

    Formulary tiering and limits

    Formulary tiering and quantity/authorization limits must be followed for each listed product.

    Drug tier and limits shown per line: Each listed product includes its Drug Tier (commonly tiers 2–5 in these sections) and, where present, Requirements/Limits such as QL and/or PA; these determine coverage and allowed dispensing quantity/timeframe.

    Examples of tier and QL/PA indicators shown in chunks 234 and 247.

    Examples of QL and PA on specific products: Examples include CLINIMIX entries with B/D notation, JYNARQUE with QL(56 EA per 28 days) plus PA, and tolvaptan/XPHOZAH entries with QL and PA—coverage requires adherence to these entries or an approved exception.

    Specific QL and PA notations are shown next to product lines (chunk 247,234).

    If a drug is not listed on the formulary, the plan does not cover it unless an exception is granted. Members and prescribers should contact Customer Service to confirm coverage and to request a formulary exception when medically necessary. The plan will provide information on alternative covered drugs for prescribers to consider, or the member may submit an exception request with a supporting statement from the prescriber explaining the medical reasons for coverage. Exception decisions are handled per the plan’s timelines (see exception decision timeframes).

    Coverage from an out-of-network pharmacy is available only in limited circumstances. For details about when out-of-network fills are allowed and any associated cost sharing, consult the plan’s Evidence of Coverage and the formulary notes; routine fills should be obtained at an in-network pharmacy to receive standard coverage.

    The table excerpts in this formulary show each product’s Drug Tier and any Requirements/Limits flags such as PA (prior authorization), QL (quantity limits) and NDS. These listings do not include detailed clinical medical‑necessity algorithms or diagnosis-level criteria in the excerpted rows; where a product row shows only tier and flags, coverage is determined by those flags and any applicable prior authorization or quantity‑limit processes described elsewhere in plan materials.

    Formulary Codes, Flags and Examples

    Formulary requirement codes and examplesmixed
    QL(180 EA per 90 days)Quantity limit example for celecoxib 200mg,400mg
    QL(270 EA per 90 days)Quantity limit example for celecoxib 100mg
    QL(540 EA per 90 days)Quantity limit example for celecoxib 50mg
    PAPrior Authorization (e.g., diclofenac epolamine patch, FLECTOR patch)
    QL(600 ML per 30 days)Quantity limit for diclofenac sodium external solution 1.5%
    QL(15 EA per 30 days)Quantity limit for fentanyl patch 72 hour
    QL(4 EA per 28 days)Quantity limit for buprenorphine patch weekly
    QL(3720 ML per 31 days)Quantity limit for methadone HCL solution 5mg/5ml
    QL(372 EA per 31 days)Quantity limit example for methadone HCL tablet 10mg
    QL(62 EA per 31 days)Quantity limit example for some morphine ER capsules / oxymorphone
    1–10 of 12
    1/2
    Formulary quantity limits (examples)mixed
    QL(372 EA per 31 days)quantity limit for multiple oxycodone tablet entries
    QL(279 ML per 31 days)quantity limit for oxycodone hydrochloride concentrate 100mg/5ml
    QL(1860 ML per 31 days)quantity limit for oxycodone hydrochloride solution 5mg/5ml
    Additional QL and PA flagsmixed
    QL(270 EA per 90 days)quantity limit shown for lidocaine patch 5%
    QL(12 EA per 90 days)quantity limit shown for some opioid reversal agents (e.g., KLOXXADO)
    QL(336 EA per 90 days)quantity limit for VOQUEZNA packs
    PAprior authorization flag as shown in table
    Formulary coding and flagsmixed
    Drug tier indicatorsEntries include 'Drug Tier = 1' through 'Drug Tier = 5' for listed products
    QL(...)Quantity limits specified in parentheses after 'QL' (examples shown across table)
    PAPrior Authorization flag shown in Requirements/Limits for multiple products
    STStep Therapy flag shown for at least oxcarbazepine er formulation
    NDSNotation appearing with certain rescue/acute products (e.g., Nayzilam, diazepam gel, Libervant, Valtoсo)
    Quantity-limited items in Requirements/Limitsmixed
    QL(93 EA per 31 days)Quantity limit for posaconazole dr tablet delayed release 100mg
    Examples of QL entriesmixed
    QL(3 ML per 84 days)Quantity limit for AIMOVIG injection 140MG/ML
    QL(6 ML per 84 days)Quantity limit for AIMOVIG injection 70MG/ML
    QL(6 ML per 84 days)Quantity limit for EMGALITY injection 120MG/ML
    QL(9 ML per 84 days)Quantity limit for EMGALITY injection 100MG/ML
    QL(18 EA per 30 days)Quantity limit for NURTEC tablet disintegrating 75MG
    Topical and injectables QL examplesmixed
    QL(180 GM per 90 days)Quantity limit shown for certain topical powders/creams (e.g., klayesta)
    QL(24 ML per 90 days)Quantity limit for dihydroergotamine mesylate solution 4mg/ml
    Quantity limits shown inlinemixed
    QL(124 EA per 31 days)Quantity limit for RUBRACA as listed
    Quantity limits shown inlinemixed
    QL(84 EA per 365 days)Quantity limit for VENCLEXTA STARTING PACK as listed
    Quantity limits shown inlinemixed
    QL(360 EA per 30 days)Quantity limit for RYTARY CAPSULE EXTENDED RELEASE as listed
    Quantity limit entries (examples)mixed
    QL(30 EA per 30 days)Quantity limit example for LYBALVI
    QL(180 EA per 30 days)Quantity limit example for OPIPZA FILM 10mg
    QL(720 ML per 90 days)Quantity limit for risperidone solution
    QL(124 EA per 31 days)Quantity limit for SOHONOS 1.5/1 mg
    QL(112 EA per 28 days)Quantity limit for PREVYMIS packet
    Formulary drug list (no procedure/diagnosis codes in this section)mixed
    No codes listed
    Quantity limit codes shownmixed
    QL(180 EA per 90 days)Quantity limit for dabigatran etexilate capsule
    QL(148 EA per 365 days)Quantity limit for ELIQUIS STARTER PACK TABLET THERAPY PACK 5MG
    QL(194 EA per 90 days)Quantity limit for ELIQUIS CAPSULE SPRINKLE 0.15MG
    QL(1164 EA per 90 days)Quantity limit example for ELIQUIS TABLET SOLUBLE 0.5MG
    QL(1552 EA per 90 days)Quantity limit example for ELIQUIS TABLET SOLUBLE 0.5MG
    QL(388 EA per 90 days)Additional ELIQUIS quantity limit entry
    Authorization flagsmixed
    PAPrior authorization required (flag used in Requirements/Limits)
    OVMOVM flag used in Requirements/Limits (used for oncology verification/management)
    Quantity limit codes shownmixed
    QL(360 GM per 90 days)quantity limit for calcipotriene cream/ointment
    QL(300 GM per 90 days)quantity limit for EUCRISA OINTMENT 2%
    QL(725.4 GM per 31 days)quantity limit for FILSUVEZ GEL 10%
    QL(30 ML per 90 days)quantity limit for FLUOROURACIL SOLUTION 2%
    QL(10 ML per 30 days)quantity limit for fluorouracil solution 5%
    Requirement/Limits codesmixed
    B/DRequirement/limit notation used for Clinimix products (B/D shown)
    Quantity limits and PA notationsmixed
    QL(56 EA per 28 days)quantity limit for JYNARQUE tablet therapy pack as listed
    QL(31 EA per 31 days)quantity limit for tolvaptan tablet 15mg
    QL(62 EA per 31 days)quantity limit for tolvaptan tablet 30mg
    QL(56 EA per 28 days); PAJYNARQUE: quantity limit and prior authorization
    PAprior authorization indicated (general)
    QL(62 EA per 31 days); PAXPHOZAH tablet quantity limit and PA
    QL(270 EA per 90 days)LOKELMA packet 5gm quantity limit
    QL(94 EA per 90 days)LOKELMA packet 10gm quantity limit
    QL(270 EA per 90 days)VELTASSA packet 8.4gm quantity limit
    QL(90 EA per 90 days)VELTASSA packet 16.8/25.2gm quantity limit
    1–10 of 12
    1/2
    Formulary UM codes and examplesmixed
    QL(90 EA per 90 days)Quantity limit example for LINZESS
    QL(180 EA per 90 days)Quantity limit example for lubiprostone
    PAPrior authorization required (appears for multiple drugs)
    OVMOperational/oncology verification marker (appears for select oncology entries)
    NDSNon-Extended Day Supply or similar marker (appears for certain products)
    inv-27: Quantity limits
    Example QL formatsQL(180 EA per 90 days); QL(3720 ML per 31 days); QL(15 EA per 30 days)
    ContextThese QL entries appear in the Analgesics and Opioid sections of the formulary as Requirements/Limits
    Action for providersEnsure prescription quantity and days supply submitted on claim align with the listed QL to avoid denial
    inv-28: Sample quantity limits
    Sample QL examplesQL(372 EA per 31 days); QL(270 EA per 90 days); QL(12 EA per 90 days); QL(336 EA per 90 days)
    Where shownOpioid reversal agents, topical analgesics (lidocaine), and VOQUEZNA therapy packs in formulary entries
    Provider noteFollow Requirements/Limits field for dispensing limits and PA flags where present
    inv-29: Quantity limit examples (exact QL values)
    Exact QL values (examples)DIFICID suspension QL(136 ML per 10 days); clobazam suspension QL(480 ML per 30 days); lacosamide solution QL(3600 ML per 90 days)
    SectionAntibacterials, Anticonvulsants and Sodium Channel Agents sections list specific QL amounts
    Clinical relevanceDispensed quantity must not exceed the stated ML/EA per timeframe
    inv-30: Quantity Limits examples
    Representative QLsQL(3600 ML per 90 days); QL(124 EA per 31 days); QL(180 EA per 90 days)
    Associated productslacosamide solution/tablets; MOTPOLY XR; donepezil disintegrating — see formulary lines for per-period units
    Provider actionVerify days-supply mapping (e.g., 31-day, 90-day) when submitting claims to ensure QL compliance
    inv-31: QL examples (EA per days)
    EA per days examplesQL(162 EA per 90 days); QL(81 EA per 90 days)
    Therapeutic classMigraine/triptan class entries list these QLs in formulary
    ImplicationAdhere to listed QL values when dispensing to avoid exceeding plan-covered amounts
    inv-32: Quantity limits examples (detailed)
    Exact examples (varied formats)QL(30 EA per 30 days); QL(180 EA per 30 days); QL(720 ML per 90 days); QL(124 EA per 31 days); QL(112 EA per 28 days)
    Products referencedLYBALVI, OPIPZA film, risperidone solution, SOHONOS, PREVYMIS packet — see lines for strength-specific QLs
    NoteSome QLs vary by strength or pack type; confirm the exact formulary line for the prescribed strength/pack
    inv-33: Quantity limits examples (PREZISTA, oseltamivir examples)
    PREZISTA & oseltamivir examplesPREZISTA tablet QL(1440 EA per 90 days) and QL(240 EA per 30 days for 150mg); oseltamivir capsule QL(168 EA per 180 days) or QL(84 EA per 180 days); oseltamivir suspension QL(1050 ML per 180 days)
    Where listedAntiviral/anti-HIV and influenza agent sections of the formulary
    Provider guidanceMatch prescribed pack/strength to the specific QL line (capsule vs suspension vs tablet pack) when requesting coverage or submitting claims
    inv-34: Examples of QL thresholds
    Sample QL thresholdsQL(2700 ML per 90 days); QL(180 EA per 90 days); QL(194 EA per 90 days)
    Therapeutic areasAnticoagulants/ELIQUIS entries, rivaroxaban suspension and related cardiovascular agents
    Operational noteSome QLs are paired with PA or other flags — check Requirements/Limits when prescribing
    inv-35: Quantity limit examples (extended list)
    Extended QL examples (selected)QL(360 EA per 90 days); QL(90 EA per 90 days); QL(2 ML per 28 days); QL(30 EA per 30 days); QL(248 EA per 31 days)
    ScopeExamples drawn from dyslipidemics, CNS stimulants, PRALUENT, tetrabenazine and other classes
    Provider reminderWhen drugs carry both QL and PA, obtain authorization and prescribe within QL to ensure coverage
    inv-36: QL for clobetasol cream/gel
    Clobetasol QLQL(180 GM per 90 days)
    Formulary locationDermatological Agents — clobetasol cream/gel/related formulations
    Dispensing implicationTotal grams dispensed per 90-day period should not exceed 180 GM under plan coverage
    inv-37: Sample quantity limits (examples)
    Sample QL setQL(90 EA per 90 days); QL(180 EA per 90 days); QL(93 EA per 31 days)
    Products illustratedLINZESS, lubiprostone, XIFAXAN and others in GI category
    Operational noteConfirm product-specific QL and timeframe (31 vs 90 vs 365 days) when prescribing or submitting PA

    Authorization, Step Therapy, Documentation and Denial Risks

    Prior Authorization

    Prior authorization required

    Obtain prior authorization for drugs marked with a PA requirement before dispensing; failure to obtain PA may result in noncoverage.

    • PA is defined in the Requirements/Limits field and requires approval before filling the prescription.
    • If authorization is not obtained the plan may not cover the drug.
    Prior Authorization

    Prior authorization requirements (OVM and oncology mention)

    For oncology antineoplastics and supportive care drugs follow the Oncology Value Management (OVM) prior‑authorization process administered by OncoHealth; failure to follow OVM/PA may lead to noncoverage.

    • OVM flag in Requirements/Limits indicates OVM prior authorization is required.
    • Providers must submit additional clinical information as requested to support OVM/PA determinations.
    Prior Authorization

    PA required for PA‑marked drugs

    If a formulary entry shows the 'PA' notation in the Requirements/Limits column, initiate the plan's prior authorization process for that specific product prior to fill.

    • PA is shown next to products in the formulary; consult the plan's PA process for required submission steps.
    Prior Authorization

    PA required for selected anticonvulsants

    Prior authorization is required for multiple branded anticonvulsant products (e.g., brivaracetam formulations, EPIDIOLEX, FINTEPLA); obtain PA per the Requirements/Limits before dispensing.

    • Brivaracetam solution and tablets list QL and PA (QL(620 ML per 31 days); PA; QL(62 EA per 31 days); PA).
    • EPIDIOLEX and other anticonvulsants are marked PA in the formulary lines.
    Prior Authorization

    PA required for select epilepsy agents

    For listed epilepsy agents such as rufinamide and multiple XCOPRI entries, secure prior authorization and respect any listed quantity limits (QL) before filling.

    • Rufinamide suspension and tablets indicate 'Requirements/Limits = PA'.
    • XCOPRI therapy packs/tablets show QL entries plus PA (examples: QL(31 EA per 31 days); PA; QL(56 EA per 365 days); PA).
    Prior Authorization

    Prior authorization required for select products (examples)

    Obtain prior authorization for the listed select products that include PA in the Requirements/Limits column (formulary examples show PA next to items such as DICLOFENAC EPOLAMINE PATCH and others).

    • DICLOFENAC EPOLAMINE PATCH is listed with Requirements/Limits = PA.
    • Check each product's Requirements/Limits field for PA notation and initiate PA if present.
    Prior Authorization

    Prior authorization required for specified drugs (specialty/high‑tier examples)

    Many specialty and high‑tier products are designated with PA in the Requirements/Limits field; providers must request prior authorization before prescribing these specialty agents.

    • Examples include AIMOVIG injections (QL; PA) and numerous oncology/specialty agents flagged PA.
    • Specialty agents often require PA and additional verification (OVM) as shown on their formulary rows.
    Prior Authorization

    Prior Authorization required for many specialty agents

    Many specialty, oncology, and biologic agents list 'Requirements/Limits = PA' (often with an OVM flag); obtain prior authorization and submit any additional verification requested.

    • Multiple agents (e.g., FRUZAQLA, GAVRETO, IBRANCE, IMBRUVICA) show Requirements/Limits = PA; OVM.
    • Paired PA/OVM flags indicate plan-managed specialty review processes must be completed prior to coverage.
    Prior Authorization

    Prior authorization / step therapy indicated

    When a product line shows 'PA' or 'ST' in Requirements/Limits, follow the corresponding prior authorization or step‑therapy processes before dispensing; PA is required where shown and ST must be met for coverage.

    • Entries designate PA (prior authorization) and ST (step therapy) in the Requirements/Limits field; comply with these administrative controls.
    • Failure to meet PA or ST requirements may result in denial of coverage.
    Prior Authorization

    Prior authorization required for select products (GLP‑1 and similar examples)

    Prior authorization is required for certain high‑use GLP‑1 and related products (examples include liraglutide, MOUNJARO, OZEMPIC, RYBELSUS) where PA is shown; secure PA and adhere to any listed quantity limits.

    • Liraglutide injection shows QL(27 ML per 90 days); PA.
    • MOUNJARO, OZEMPIC and related agents display QL values and PA in Requirements/Limits.
    Prior Authorization

    Prior authorization for biologic/hematopoietic agents

    For listed biologic and hematopoietic agents (e.g., FULPHILA, NEULASTA, ARANESP, EPOGEN), obtain prior authorization and, where indicated, submit OVM documentation; lack of PA may trigger denial.

    • FULPHILA and NEULASTA entries include 'Requirements/Limits = PA; OVM'.
    • Providers must follow the PA/OVM process for these injectable biologic agents.
    Prior Authorization

    Prior authorization required for specified products (examples)

    For numerous select products (e.g., ATTRUBY, VYNDAMAX, VECAMYL) that display PA in Requirements/Limits, initiate prior authorization prior to prescribing to avoid coverage denials.

    • ATTRUBY lists QL(112 EA per 28 days); PA.
    • VECAMYL and VYNDAMAX entries show PA (VYNDAMAX also has QL values).
    Prior Authorization

    Prior authorization required for select products (examples)

    Certain listed products require prior authorization before coverage (PA flag appears next to the product row); providers must request PA when prescribing these items.

    • Examples: PRALUENT (QL; PA), NEXLETOL/NEXLIZET (QL; PA) and others are marked PA in the formulary.
    • Obtain PA according to plan instructions for each PA‑flagged product.
    Documentation Required

    Prior authorization and quantity limits

    Some dermatologic and specialty agents include both a PA indicator and a quantity limit (QL); obtain PA and ensure prescriptions conform to the listed QL to avoid denial.

    • FILSUVEZ shows QL(725.4 GM per 31 days); PA.
    • Calcipotriene products list QL(360 GM per 90 days) and PA as applicable.
    Prior Authorization

    PA required for select agents

    Initiate prior authorization for the select agents listed with 'PA' in their product rows (e.g., JYNARQUE, tolvaptan, XPHOZAH) prior to fill to ensure coverage.

    • JYNARQUE therapy pack: QL(56 EA per 28 days); PA.
    • Tolvaptan entries show PA with QL values for specific strengths.
    Prior Authorization

    Prior authorization required for specific drugs (MOVANTIK, GATTEX examples)

    Prior authorization is required for specific listed drugs such as MOVANTIK, GATTEX, MYALEPT, VOWST, and XIFAXAN as indicated by 'PA' in Requirements/Limits; submit PA requests for these products.

    • GATTEX and MYALEPT are shown with Requirements/Limits = PA.
    • VOWST and XIFAXAN include QL entries and PA where noted.
    Step Therapy

    Step therapy requirement (general)

    Follow step therapy where indicated: some drugs require trial of preferred therapies first (ST flag); if ST applies, coverage for the listed product depends on meeting the step requirement.

    • Step Therapy (ST) is defined in the Requirements/Limits field and requires trying specified drugs first.
    • If a step is unmet, coverage for the alternative drug may be denied until criteria are satisfied.
    Step Therapy

    Step therapy (general definition/use)

    Step therapy may require trying a specified drug first before coverage of alternatives; check the formulary 'Requirements/Limits' field for the ST flag and follow plan procedures.

    • The formulary introduction explains ST meaning and directs providers to the Requirements/Limits column to identify ST.
    • EXXUA shows Requirements/Limits = QL(...); ST indicating step controls on that product.
    Note

    No action specified

    The inventory placeholder contains no actionable requirement in the source — no provider action specified here.

    Step Therapy

    Step therapy flag — oxcarbazepine ER

    Oxcarbazepine extended‑release tablets are labeled 'ST' in Requirements/Limits; follow the step therapy requirement for the ER formulation before coverage.

    • Oxcarbazepine ER tablet (300mg, 600mg) lists Requirements/Limits = ST.
    • EXXUA titration pack also shows ST among its Requirements/Limits.
    Step Therapy

    Step therapy controls (oxcarbazepine ER, EXXUA)

    Products labeled 'ST' (for example oxcarbazepine ER and EXXUA) are subject to step therapy controls; ensure step requirements are documented when requesting coverage.

    • EXXUA: Requirements/Limits = QL(32 EA per 14 days); ST.
    • Oxcarbazepine ER: Requirements/Limits = ST.
    Step Therapy

    Step therapy flags present (general)

    Step therapy flags appear on multiple agents; check each product's Requirements/Limits and follow plan‑specified step protocols when prescribing.

    • Several antipsychotics and other classes show ST in Requirements/Limits (see LAI and other entries).
    • If ST applies, documentation of prior trials may be required for approval.
    Step Therapy

    Step or specialty program flags (RYTARY example)

    RYTARY's formulary row includes 'Requirements/Limits = QL(...); ST' indicating a quantity limit plus a step‑therapy or specialty program flag — comply with both when requesting coverage.

    • RYTARY lists QL(360 EA per 30 days); ST.
    • Providers should document trial history and prescribe within the QL to avoid denials.
    Step Therapy

    Step therapy present for specific agents (LAI and oral antipsychotics)

    Step therapy is specified for several long‑acting injectables and oral agents (examples include ARISTADA, INVEGA SUSTENNA/TRINZA, PERSERIS); obtain necessary documentation that step requirements were met before fill.

    • ARISTADA and INVEGA SUSTENNA/TRINZA list Requirements/Limits = ST.
    • PERSERIS is also shown with ST in Requirements/Limits.
    Step Therapy

    Step therapy noted for select insulins (APIDRA example)

    Some insulin products (e.g., APIDRA SOLOSTAR) include an 'ST' indicator; follow step‑therapy requirements per the formulary when prescribing these insulin products.

    • APIDRA lists Requirements/Limits = ST.
    • Check the formulary line for ST and document prior therapy trials where required.
    Note

    No action specified

    This inventory placeholder contains no provider action text in the source.

    Note

    Step therapy not specified in this section

    No explicit step‑therapy algorithms are provided in this excerpt; where ST is shown on a product line, check plan criteria or contact the plan for drug‑specific step rules.

    • The document shows ST flags but does not list full step algorithms in these chunks.
    • Contact plan resources or the online PA/ST documentation for specific step requirements.
    Step Therapy

    Step therapy present (JARDIANCE example)

    JARDIANCE is shown with 'ST' in Requirements/Limits; ensure step‑therapy criteria are met before coverage is requested.

    • JARDIANCE entry: Requirements/Limits = QL(90 EA per 90 days); ST.
    • Document prior trials per plan guidance to support coverage.
    Note

    No action specified

    This inventory placeholder contains no provider action text in the source.

    Note
    Note
    Documentation Required

    Exception request documentation requirements

    When requesting an exception to the formulary or to waive a PA/QL/ST requirement, the prescriber must provide a supporting statement explaining the medical rationale; the plan generally decides within 72 hours or 24 hours for expedited requests.

    • Prescriber must explain why formulary alternatives or applying the restriction would not be as effective or would cause harm.
    • Standard exception decisions: within 72 hours; expedited: within 24 hours.
    Documentation Required

    Required documentation for B/D determination and OVM

    For B/D coverage determinations and Oncology Value Management cases, submit the additional clinical and setting information requested by the plan to support the B/D determination or OVM prior authorization.

    • B/D notation means coverage may depend on whether the drug is covered under Medicare Part B or D and may require submission of use/setting details.
    • OVM entries require OncoHealth submission of additional clinical information.
    Billing Rule

    Quantity limits (provider action notice)

    Observe and document quantity limits (QL) shown for many products; submit days‑supply and quantity consistent with the listed QL to avoid claim denials.

    • Examples include QL(372 EA per 31 days) for oxycodone tablets and QL(136 ML per 10 days) for DIFICID suspension.
    • When prescribing, ensure the dispense quantity and days' supply align with the QL.
    Documentation Required

    Quantity limit documentation (specific examples)

    Document exact quantity limits shown for specific products when submitting claims or PA requests (e.g., DIFICID suspension QL(136 ML per 10 days); DIFICID tablet QL(20 EA per 10 days)).

    • Provide prescription quantity and days' supply that match QL entries to reduce risk of denial.
    • Include QL rationale in PA/exception documentation when relevant.
    Documentation Required

    Formulary annotations — tier and flags

    Formulary lines include operational flags (PA, QL, ST, OVM, NDS); follow the Requirements/Limits field on each product row when submitting claims or authorization requests.

    • Requirements/Limits is the authoritative field for utilization controls per the formulary introduction.
    • Check each product's line for PA, QL, ST, OVM before dispensing.
    Documentation Required

    Follow Requirements/Limits field

    Use the 'Requirements/Limits' field on the formulary as the operative guide: it indicates QL, PA, OVM, ST or other administrative flags that must be followed per plan instructions.

    • The introduction explains the meaning of QL, PA, ST, OVM and NDS used in the Requirements/Limits column.
    • Follow plan processes tied to the flags shown when filing claims or PA requests.
    Documentation Required

    Quantity limit documentation (RUBRACA example)

    When products list explicit quantity limits (QL) and PA together (e.g., RUBRACA QL(124 EA per 31 days); PA), ensure PA submissions and claims reflect the prescribed quantity and days' supply consistent with the QL.

    • RUBRACA lists QL(124 EA per 31 days); PA.
    • VENCLEXTA STARTING PACK lists QL(84 EA per 365 days); PA.
    Documentation Required

    Quantity limits documented (examples)

    Several products include QL values (e.g., LYBALVI QL(30 EA per 30 days); paliperidone ER QL(180 EA per 90 days)); ensure dispensing and authorization requests conform to these limits.

    • OPIPZA film entries include QL values and PA notation.
    • Paliperidone ER has QL(180 EA per 90 days) listed.
    Documentation Required

    Adhere to listed quantity limits

    Adhere to listed quantity limits (QL) when prescribing and documenting days' supply (e.g., PREZISTA QL(1440 EA per 90 days); oseltamivir QL(168 EA per 180 days)); mismatched quantities may lead to denial.

    • Provide prescription quantity and days' supply consistent with the QL to avoid coverage issues.
    • Include justification in PA or exception requests if exceeding a QL is clinically necessary.
    Prior Authorization

    PA required for select agents (hematologic biologics)

    Prior authorization is required for selected hematologic/biologic injectable agents (e.g., ARANESP ALBUMIN FREE, EPOGEN, PROCRIT, NEULASTA, FULPHILA); obtain PA and submit required clinical documentation.

    • FULPHILA and NEULASTA include Requirements/Limits = PA; OVM.
    • ARANESP, EPOGEN, PROCRIT are listed with PA in the Requirements/Limits field.
    Billing Rule

    Quantity‑limit compliance

    Comply with quantity‑limit enforcement: claims must conform to listed QLs (e.g., QL(90 EA per 90 days), QL(180 EA per 90 days)); submit PA or exception requests if clinical need exceeds the QL.

    • Document days' supply and quantity consistent with the QL at claim/PA submission.
    • Use the exception process with prescriber supporting statement if exceeding the QL is medically necessary.
    Prior Authorization

    PA requirement — operational reminder

    This operational reminder reiterates that when the formulary shows 'PA' the prescriber must obtain prior authorization before filling the product to secure coverage.

    • PA flag on a product row indicates prior authorization is required.
    • Claims submitted without required PA may be denied.
    Documentation Required

    Documentation of QL and PA

    Document QL and PA indicators on the prescription and in any authorization requests; include quantity, days' supply, and supporting clinical information that match the formulary's QL/PA entries.

    • Examples of QL values: '360 GM per 90 days', '725.4 GM per 31 days'.
    • Show PA status on authorization forms and include matching quantity details.
    Documentation Required

    Quantity limits documented (JYNARQUE, tolvaptan examples)

    Certain products list specific QL values (e.g., JYNARQUE QL(56 EA per 28 days); tolvaptan entries) and also require PA; obtain PA and ensure dispense quantity matches the QL.

    • JYNARQUE: QL(56 EA per 28 days); PA.
    • Tolvaptan entries include QL values and PA (generic and brand distinctions noted).
    Denial Risk

    Prior authorization — denial risk if not obtained

    Many products are designated with PA and may have accompanying limits (QL or OVM); failure to obtain PA or to meet limits increases the risk of denial — submit PA and document compliance with limits.

    • The formulary introduction states missing PA may result in noncoverage.
    • Utilization management flags (PA, ST, QL) may trigger denials if unmet.
    Denial Risk

    Prior authorization and Oncology Value Management — denial risk

    Failure to obtain required PA or to follow Oncology Value Management (OVM) for antineoplastics/supportive care may result in noncoverage; providers must submit OVM/PA documentation through the OncoHealth process.

    • OVM is defined as the PA program for oncology drugs administered by OncoHealth.
    • OVM/PA entries on oncology agents indicate additional verification steps required.
    Denial Risk

    Prior authorization indicated — denial risk

    Entries flagged 'PA' (such as lidocaine patch, ARIKAYCE, VOQUEZNA packs) indicate prior authorization is required; not securing PA may cause the claim to be denied.

    • Lidocaine patch and topical entries show QL and PA notations in Requirements/Limits.
    • ARIKAYCE and VOQUEZNA therapy packs are listed with PA flags.
    Denial Risk

    PA requirements for selected anticonvulsants — denial risk

    Prior authorization is listed for multiple anticonvulsants (e.g., brivaracetam, EPIDIOLEX, FINTEPLA, FYCOMPA); incomplete PA submissions risk denial of coverage.

    • Brivaracetam entries show QL and PA (QL(620 ML per 31 days); PA).
    • EPIDIOLEX and FINTEPLA entries are marked PA in the formulary.
    Denial Risk

    XCOPRI PA and QL — denial risk

    XCOPRI therapy packs and tablets include both PA and quantity limits (QL); requests that do not meet PA or QL requirements may be denied.

    • XCOPRI therapy packs list QL examples (e.g., QL(168 EA per 84 days); QL(56 EA per 365 days)) plus PA.
    • XCOPRI tablets include QL(31 EA per 31 days); PA.
    Denial Risk

    Prior Authorization indicated — denial risk

    Drugs marked 'PA' (e.g., rufinamide, multiple XCOPRI entries) require prior authorization; lack of PA may result in coverage denial.

    • Rufinamide suspension and tablets are marked 'PA' in Requirements/Limits.
    • Formulary introduction states missing PA may lead to noncoverage.
    Denial Risk

    Step therapy indicated — denial risk if unmet

    Products annotated with 'ST' such as oxcarbazepine ER and EXXUA may be denied if step therapy requirements are not satisfied; document prior therapy trials when submitting PA or claims.

    • EXXUA: Requirements/Limits = QL(...); ST.
    • Oxcarbazepine ER explicitly lists ST in Requirements/Limits.
    Denial Risk

    Prior authorization required for listed products — denial risk

    Some listed products require prior authorization as noted in the Requirements/Limits field; claims submitted without required PA are at risk of denial.

    • The formulary's Requirements/Limits field identifies PA requirements for individual drugs.
    • Providers should confirm PA status prior to dispensing to avoid claim denials.
    Denial Risk

    PA & OVM requirement common — denial risk

    Claims for many specialty oncology and targeted agents listing 'PA; OVM' may be denied if PA/OVM are not completed; ensure OVM submissions are routed through OncoHealth as required.

    • Numerous oncology/targeted therapies show 'PA; OVM' in Requirements/Limits (examples throughout chunks 108–117).
    • OVM submissions require additional clinical information via the plan's oncology management process.
    Denial Risk

    Utilization management may trigger denial

    Utilization management flags (PA, ST, QL) applied to drugs may trigger coverage denial if the requirements are not met; verify and document compliance before submitting claims.

    • The formulary shows PA, ST and QL codes that indicate utilization controls.
    • Noncompliance with these controls can result in denial.
    Prior Authorization

    PA required for Humulin R U‑500

    Humulin R U-500 (Kwikpen and other concentrated forms) requires prior authorization; absence of PA may result in denial of coverage.

    • HUMULIN R U-500 and its Kwikpen formulation are identified with PA in the formulary.
    • Obtain PA before dispensing concentrated insulin formulations.
    Prior Authorization

    PA and QL indicated for select injectables

    Some hematologic biologic injectables (e.g., ARANESP, EPOGEN, PROCRIT, NEULASTA, FULPHILA) require prior authorization and may also have quantity limits; secure PA and document quantity/days' supply.

    • NEULASTA and FULPHILA entries list Requirements/Limits = PA; OVM.
    • Provide required clinical documentation for PA to avoid denial.
    Denial Risk

    Prior authorization required for select products — denial risk

    Some listed products (e.g., ATTRUBY, JYNARQUE, tolvaptan) show 'PA' in Requirements/Limits; obtain prior authorization to prevent denials.

    • ATTRUBY: QL(112 EA per 28 days); PA.
    • JYNARQUE and tolvaptan entries list PA alongside QL values.
    Prior Authorization

    PA for specialty/high‑tier agents

    For listed specialty/high‑tier agents such as VECAMYL and VYNDAMAX that carry a PA flag, secure prior authorization before treatment initiation to ensure coverage.

    • VECAMYL: Requirements/Limits = PA.
    • VYNDAMAX: Requirements/Limits = QL(31 EA per 31 days); PA.
    Prior Authorization

    Prior authorization indicated for select drugs

    Coverage for numerous listed products (e.g., NEXLETOL, NEXLIZET, PRALUENT, KERENDIA, VERQUVO) may be subject to prior authorization; confirm PA requirements and submit appropriate documentation.

    • NEXLETOL/NEXLIZET entries show QL and PA.
    • PRALUENT lists QL(2 ML per 28 days); PA.
    Denial Risk

    Prior authorization/Quantity limit denials

    Certain products apply both PA and QL controls; failure to obtain PA or to adhere to QL may result in denial — ensure PA approvals and dispense within QL limits.

    • Examples include dermatologic agents and specialty injectables with both PA and QL flags.
    • Document PA approval and match dispense quantity/days' supply to QL.
    Prior Authorization

    Prior authorization indicated for select products

    Some products require prior authorization (PA) — for example JYNARQUE and tolvaptan entries list PA in Requirements/Limits; request PA before dispensing.

    • JYNARQUE therapy pack: QL(56 EA per 28 days); PA.
    • Tolvaptan entries include PA and QL values for specific strengths.
    Prior Authorization

    Prior authorization and limits noted on select drugs

    Coverage for listed specialty drugs such as MOVANTIK, GATTEX, MYALEPT is subject to prior authorization per the Requirements/Limits field; obtain PA and provide requested clinical details.

    • GATTEX and MYALEPT show Requirements/Limits = PA.
    • MOVANTIK and others are identified with PA in the formulary listings.
    Note

    Step Therapy Flags and Affected Products

    Coverage noteDetails
    Some drugs require trying preferred drugs first before coverage of alternatives (step therapy).
    Step Therapy (ST) is defined in the formulary: the plan may require you to try a specified drug first before covering another drug for the same condition.
    Plan noteMeaning
    ST flag appears in the Requirements/Limits column of the formulary.
    ST = Step Therapy: indicates the plan requires trying a specified drug first before covering another drug for that condition; if the required trial fails, the alternative may then be covered.
    Product examplesFormulary implication
    ARIKAYCE and VOQUEZNA packs are listed on the formulary with utilization controls (e.g., PA) for specialty products.
    Branded specialty products may be subject to prior authorization and other specialty-review processes; step therapy may apply where the ST flag is present.
    AgentRequirements/Limits
    oxcarbazepine er tablet extended release 24 hour (300 mg, 600 mg)
    Requirements/Limits = ST (Step therapy indicated for the extended‑release formulation)
    AgentRequirements/Limits
    oxcarbazepine er (extended‑release) and EXXUA titration pack
    Formulary entries show 'ST' for oxcarbazepine er and 'QL(...); ST' for EXXUA indicating step therapy controls apply
    Agents annotated 'ST'Plan action
    oxcarbazepine er (extended‑release)
    ST indicated in Requirements/Limits — step therapy required before coverage of listed formulation
    Annotated agentsInterpretation
    RYTARY capsule extended release
    Requirements/Limits = QL(360 EA per 30 days); ST — listing indicates a quantity limit and that step therapy or a specialty program may apply
    Antipsychotic examplesRequirements/Limits
    ARISTADA (initio and maintenance), ARISTADA formulations, INVEGA SUSTENNA, ABILIFY MAINTENA, PERSERIS, REXULTI and similar LAI/oral antipsychotics
    Multiple long‑acting injectable and oral antipsychotic entries include 'Requirements/Limits = ST' indicating step therapy is specified for these agents
    ProductRequirements/Limits
    APIDRA Injection 100 UNIT/ML
    Requirements/Limits = ST — formulary indicates step therapy applies to this insulin product
    Prior authorization noteImplication
    Some drugs require prior authorization (PA) before the prescription can be filled.
    If PA is required and not obtained, the plan may not cover the drug — entries marked 'PA' in Requirements/Limits indicate this requirement.
    AgentRequirements/Limits
    JARDIANCE tablet 10 mg, 25 mg
    Requirements/Limits = QL(90 EA per 90 days); ST — formulary shows JARDIANCE is marked with 'ST' indicating a step therapy requirement applies
    Agent groupRequirement flags
    Selected high‑tier dermatology and specialty injectables (examples within Dermatological and Biologic sections)
    Formulary lines in these sections show 'PA' and/or QL flags indicating prior authorization and quantity limits apply to selected high‑tier dermatology and specialty injectable products
    ProductsRequirements/Limits
    tolvaptan (JYNARQUE / therapy packs) and JYNARQUE tablet therapy pack
    Entries show QL (e.g., QL(56 EA per 28 days)) and PA — Requirements/Limits include 'PA' indicating prior authorization is required for coverage

    Per-Product Quantity Limits (Selected Examples)

    inv-144: pioglitazone example (31 tablets per prescription)
    Pioglitazone example31 tablets per prescription (example provided in formulary overview)
    ContextListed as an example of typical per-prescription limit in the formulary introduction
    Provider actionCheck days supply and prescription size to align with the plan's example limits when dispensing
    inv-145: various listed opioids and analgesics — QL examples
    Opioid/analgesic QL examplesQL(15 EA per 30 days) fentanyl patch; QL(3720 ML per 31 days) methadone solution; QL(372 EA per 31 days) methadone tablet; NDS flags for many opioid products
    SectionAnalgesics and Opioid Analgesics sections of the formulary
    Dispensing noteMany opioid products carry NDS (Non-Extended Day Supply) and QLs — typically 30 or 31-day maximums for retail fills
    inv-146: oxycodone hydrochloride tablet QL example
    Oxycodone tablet QLQL(372 EA per 31 days)
    Formulary lineOxycodone hydrochloride tablet entries show this QL in Analgesics section
    Claim guidanceSubmit days supply consistent with 31-day QL to avoid exceeding covered quantity
    inv-147: oxycodone concentrate QL example
    Oxycodone concentrate QLQL(279 ML per 31 days)
    Formulary locationOxycodone hydrochloride concentrate 100mg/5ml — Requirements/Limits field
    Dispensing implicationEnsure ML dispensed per 31-day period does not exceed 279 ML for coverage
    inv-148: lidocaine patch 5% QL example
    Lidocaine patch 5% QLQL(270 EA per 90 days)
    Formulary noteListed in Local Anesthetics/Analgesics section with QL and NDS/PA markers
    Provider guidanceObserve 90-day aggregate limit when dispensing multiple patches over time
    inv-149: KLOXXADO LIQUID QL example
    KLOXXADO liquid QLQL(12 EA per 90 days)
    Therapeutic classOpioid reversal agents — QL shown alongside NDS flags
    Clinical noteLimit intended to cover rescue doses while controlling utilization
    inv-150: VOQUEZNA therapy pack QL example
    VOQUEZNA therapy pack QLQL(336 EA per 90 days)
    Formulary entryVOQUEZNA dual/triple pak therapy packs listed with QL and PA
    Authorization notePA accompanies the QL for these therapy packs — obtain PA as required
    inv-151: DIFICID suspension QL example
    DIFICID suspension QLQL(136 ML per 10 days)
    DIFICID tablet QLQL(20 EA per 10 days)
    SectionMacrolides/antibacterials — specific short-course QLs shown
    inv-152: DIFICID tablet QL example
    DIFICID tablet QL20 EA per 10 days
    ContextListed adjacent to suspension entry in formulary antibacterial section
    Dispensing noteMatches typical course durations — dispense per QL timeframe
    inv-153: brivaracetam solution QL example
    Brivaracetam solution QLQL(620 ML per 31 days)
    Authorization flagPA indicated alongside the QL for solution formulation
    Provider actionInclude PA documentation when requesting coverage for solution form
    inv-154: brivaracetam tablet QL example
    Brivaracetam tablet QLQL(62 EA per 31 days)
    Formulary noteTablet strengths listed with same QL and PA requirement
    Dispensing guidanceSubmit days-supply consistent with 31-day QL
    inv-155: MINOCYCLINE ER tablet QL example
    MINOCYCLINE ER tablet QLQL(90 EA per 90 days)
    SectionTetracyclines/antibacterials — ER tablet QL shown
    NoteApplies to extended-release formulations as listed
    inv-156: clobazam suspension QL example
    Clobazam suspension QLQL(480 ML per 30 days)
    Clobazam tablet QLQL(60 EA per 30 days)
    Formulary contextAnticonvulsant listings include both suspension and tablet QLs
    inv-157: clobazam tablet QL example
    Clobazam tablet QLQL(60 EA per 30 days)
    Provider noteEnsure strength-specific tablet QL applied when dispensing
    AuthorizationPA appears elsewhere for some anticonvulsants — check Requirements/Limits
    inv-158: gabapentin capsule QL example
    Gabapentin capsule QLQL(810 EA per 90 days)
    Gabapentin solution QLQL(6480 ML per 90 days)
    Dispensing noteLarge aggregate QLs reflect chronic therapy supplies — map days-supply accordingly
    inv-159: gabapentin solution QL example
    Gabapentin solution QLQL(6480 ML per 90 days)
    Formulary lineSolution formulation listed with ML-based QL in anticonvulsant section
    Provider actionUse ML units when submitting dispensing quantity for liquid formulations
    inv-160: lacosamide solution QL example
    Lacosamide solution QLQL(3600 ML per 90 days)
    Lacosamide tablet QLQL(180 EA per 90 days) or QL(360 EA per 90 days) depending on strength
    Formulary guidanceLacosamide entries specify ML and EA QLs for solution vs tablet formulations
    inv-161: lacosamide tablet QL example
    Lacosamide tablet QLsQL(180 EA per 90 days) for 100/150/200mg; QL(360 EA per 90 days) for 50mg
    Provider noteCheck strength-specific QL when prescribing different tablet strengths
    Operational tipCombine tablet counts across strengths when validating total covered quantity
    inv-162: XCOPRI tablet QL example
    XCOPRI tablet QLQL(31 EA per 31 days)
    XCOPRI therapy pack examplesQL(168 EA per 84 days); QL(56 EA per 365 days); QL(56 EA per 28 days) depending on pack and dose
    AuthorizationPA accompanies XCOPRI entries — ensure PA plus QL compliance
    inv-163: XCOPRI therapy pack QL examples
    XCOPRI therapy pack QLsExamples include QL(168 EA per 84 days), QL(56 EA per 365 days), QL(56 EA per 28 days)
    Clinical noteTherapy pack QLs vary by dose and pack type — reference exact pack line for coverage
    Provider actionWhen prescribing a therapy pack, indicate pack type on PA/claim to match formulary QL
    inv-164: minocycline hydrochloride ER tablet QL example
    Minocycline HCl ER tablet QLQL(90 EA per 90 days)
    Formulary locationMinocycline ER entries in antibacterial class list this QL
    Dispensing implicationApply 90-day aggregate when calculating fills for extended-release formulation
    inv-165: LIBERVANT FILM QL example
    LIBERVANT FILM QLQL(10 EA per 30 days)
    Therapeutic classAnticonvulsant/rescue therapy — film formulations have short supply QLs
    Provider notePrescribe appropriate quantity for rescue use and match days supply to QL
    inv-166: VALTOCO QL example
    VALTOCO QLQL(10 EA per 30 days)
    Formulary contextRescue/acute nasal liquid therapy packs — limited per 30 days
    Operational noteValtoсo entries include NDS flags; ensure dispense quantities match QL
    inv-167: ZTALMY suspension QL example
    ZTALMY suspension QLQL(1116 ML per 31 days)
    Formulary lineSodium channel agent/anticonvulsant listings show large ML QL for suspension
    Dispensing guidanceLiquid volume limits apply per 31-day period — confirm when calculating supply
    inv-168: lacosamide solution 10mg/ml QL example
    Lacosamide solution 10mg/ml QLQL(3600 ML per 90 days)
    UnitsML per 90 days — liquid concentration specified in formulary line
    Provider actionUse ML units on claims for liquid lacosamide to align with QL
    inv-169: lacosamide tablet 100/150/200mg QL example
    Lacosamide tablets (100/150/200mg) QLQL(180 EA per 90 days)
    Formulary noteHigher-strength tablets share same 90-day EA limit as listed
    Dispensing reminderAggregate counts across strengths when applying QL for coverage
    inv-170: lacosamide tablet 50mg QL example
    Lacosamide 50mg tablet QLQL(360 EA per 90 days)
    ContextLower-strength tablet has a larger EA QL reflecting dosing differences
    Operational tipEnsure dose-specific QL is used when calculating permitted quantity
    inv-171: MOTPOLY XR 100mg QL example
    MOTPOLY XR 100mg QLQL(124 EA per 31 days)
    Other strengths150mg/200mg strengths have different QLs (e.g., QL(62 EA per 31 days))
    AuthorizationPA is listed with MOTPOLY XR — obtain PA where required
    inv-172: donepezil disintegrating 10mg QL example
    Donepezil disintegrating 10mg QLQL(180 EA per 90 days)
    Therapeutic classAntidementia agents — donepezil formulations have 90-day QLs specified
    Provider reminderMap prescription fills to 90-day QL for maintenance therapy
    inv-173: MEMANTINE HCL TITRATION PAK TABLET QL example
    Memantine titration pack QLQL(98 EA per 365 days)
    Formulary locationNMDA receptor antagonist entries include the titration pack with annual QL
    Operational noteYearly pack limits differ from monthly/90-day QLs — check pack-specific line
    inv-174: klayesta powder QL example
    Klayesta powder QLQL(180 GM per 90 days)
    SectionTopical/powder dermatological entries list gram-based QLs
    Dispensing guidanceTrack total grams dispensed across fills to remain within 90-day QL
    inv-175: nyamyc powder QL example
    Nyamyc powder QLQL(180 GM per 90 days)
    Formulary noteListed with other topical powders/creams with gram-based QLs
    Provider implicationApply gram QLs for dispensing topical powders to avoid exceeding coverage
    inv-176: AIMOVIG INJECTION QL example
    AIMOVIG injection QLQL(3 ML per 84 days) for 140mg/ML; QL(6 ML per 84 days) for 70mg/ML
    AuthorizationPA accompanies AIMOVIG entries — obtain PA and adhere to ML-based QL
    Clinical noteML-based QLs reflect administration schedule for CGRP agents
    inv-177: posaconazole DR tablet QL example
    Posaconazole DR tablet QLQL(93 EA per 31 days)
    AuthorizationPA is indicated alongside the QL for posaconazole delayed-release tablets
    Provider actionInclude PA documentation when requesting coverage and submit appropriate days supply
    inv-178: RUBRACA QL example
    RUBRACA QLQL(124 EA per 31 days)
    Therapeutic classOncology agent — QL shown with PA in Requirements/Limits
    Provider guidanceObtain PA and prescribe within the 31-day EA limit for coverage
    inv-179: VENCLEXTA STARTING PACK QL example
    VENCLEXTA starting pack QLQL(84 EA per 365 days)
    Formulary contextStarting packs and induction dosing have annual QLs listed separately from maintenance tablets
    AuthorizationPA/OVM may accompany oncology starter packs — follow plan PA process
    inv-180: RYTARY QL example
    RYTARY capsule QLQL(360 EA per 30 days)
    Additional flagST (step therapy) is indicated alongside the QL for RYTARY
    Provider actionWhen prescribing RYTARY, confirm step therapy requirements and adhere to 30-day EA QL
    inv-181: LYBALVI QL example
    LYBALVI QLQL(30 EA per 30 days)
    AuthorizationPA is listed with LYBALVI — obtain PA where required
    Formulary noteAntipsychotic/related class entries may include both QL and PA
    inv-182: OPIPZA FILM QL examples
    OPIPZA film QLsQL examples: QL(180 EA per 30 days); QL(90 EA per 30 days); QL(60 EA per 30 days) by strength
    AuthorizationPA accompanies OPIPZA film entries — PA plus QL must be satisfied
    Provider noteMatch strength-specific QL on claim/PA submission
    inv-183: paliperidone ER tablet QL example
    Paliperidone ER tablet QLQL(180 EA per 90 days)
    Formulary contextLong-acting antipsychotic oral formulations list 90-day EA QLs
    Operational tipApply 90-day aggregate when validating refill requests
    inv-184: PERSERIS (listed)
    PERSERIS QL/flagPERSERIS injection listed with ST (step therapy)
    Formulary notePERSERIS shows step therapy requirement rather than a numeric QL in the extract
    Provider actionFollow step therapy rules for PERSERIS per Requirements/Limits when requesting coverage
    inv-185: SOHONOS QL examples by strength
    SOHONOS QLs by strengthQL(124 EA per 31 days); QL(62 EA per 31 days); QL(93 EA per 31 days) depending on strength
    AuthorizationPA accompanies SOHONOS entries — obtain PA plus adhere to strength-specific QL
    Provider noteSpecify strength when submitting PA to match the formulary QL line
    inv-186: PREVYMIS packet QL example
    PREVYMIS packet QLQL(112 EA per 28 days) for tablets vs QL(28 EA per 28 days) for packet — see line specifics
    AuthorizationPA accompanies PREVYMIS packet entries — follow PA process
    Operational noteDifferent pack types (packet vs tablet) have distinct QLs and must be billed accordingly
    inv-187: PREZISTA TABLET 75MG QL example
    PREZISTA 75mg QLQL(1440 EA per 90 days)
    Formulary notePREZISTA tablet strengths have different QLs; 150mg line shows QL(240 EA per 30 days)
    Provider actionSelect correct strength and corresponding QL when submitting claims/PA
    inv-188: PREZISTA TABLET 150MG QL example
    PREZISTA 150mg QLQL(240 EA per 30 days)
    ContextHigher-strength PREZISTA tablet has different QL timeframe (30 days) compared with other strengths
    Provider noteVerify the strength-specific QL when prescribing high-strength antivirals
    inv-189: oseltamivir capsule QL examples
    Oseltamivir capsule QLsQL(168 EA per 180 days) or QL(84 EA per 180 days)
    Oseltamivir suspension QLQL(1050 ML per 180 days)
    Dispensing guidanceDifferent formulations and indications carry different QLs — reference the exact formulary line
    inv-190: oseltamivir suspension QL example
    Oseltamivir suspension QLQL(1050 ML per 180 days)
    Formulary contextSuspension reconstituted ML-based QL for pediatric/other uses
    Provider noteUse ML units when submitting claims for suspension formulations to match QL
    inv-191: LAGEVRIO capsule QL example
    LAGEVRIO capsule QLQL(40 EA per 30 days)
    PAXLOVID pack examplesQL(22 EA per 30 days); QL(40 EA per 30 days); QL(60 EA per 30 days) depending on pack
    Provider guidanceMatch therapy pack type and days supply to the formulary QL when billing
    inv-192: PAXLOVID therapy pack QL examples
    PAXLOVID therapy pack QLsQL(22 EA per 30 days); QL(40 EA per 30 days); QL(60 EA per 30 days) by pack
    Clinical notePack contents determine the EA QL — indicate pack on claim/PA to ensure correct coverage
    Operational tipVerify pack-specific QL before authorizing or dispensing
    inv-193: GLP-1 and related agents QL examples
    GLP-1 / related agents QLsExamples: liraglutide QL(27 ML per 90 days); MOUNJARO QL(2 ML per 28 days); OZEMPIC QL(3 ML per 28 days); RYBELSUS and others have strength-specific QLs
    AuthorizationMany GLP-1 agents carry PA in Requirements/Limits in addition to QL
    Provider actionObtain PA where indicated and prescribe within the ML/EA QLs shown
    inv-194: dabigatran etexilate QL example
    Dabigatran QLQL(180 EA per 90 days)
    Formulary contextAnticoagulant entries list 90-day EA QLs for oral direct thrombin inhibitors
    Provider noteAlign days supply with 90-day QL on claim submissions
    inv-195: ELIQUIS STARTER PACK QL example
    ELIQUIS starter pack QLQL(148 EA per 365 days)
    ELIQUIS capsule sprinkle QLQL(194 EA per 90 days)
    ELIQUIS soluble tablet examplesMultiple QLs (QL(1164 EA per 90 days); QL(1552 EA per 90 days); QL(388 EA per 90 days)) depending on presentation
    inv-196: ELIQUIS CAPSULE SPRINKLE QL example
    ELIQUIS capsule sprinkle QLQL(194 EA per 90 days)
    ContextSprinkle/capsule presentations have specific QLs — check formulation when prescribing
    Provider noteSubmit appropriate formulation code on PA/claim to match QL
    inv-197: ELIQUIS TABLET SOLUBLE QL examples
    ELIQUIS soluble tablet QLsExamples include QL(1164 EA per 90 days); QL(1552 EA per 90 days); QL(388 EA per 90 days)
    UsageMultiple entries reflect dosing equivalencies (e.g., 3x0.5mg = 1.5mg) — see formulary for mapping
    Provider guidanceEnsure dose-conversion considerations are applied when calculating permitted EA per 90 days
    inv-198: rivaroxaban suspension QL example
    Rivaroxaban suspension QLQL(2700 ML per 90 days)
    Formulary noteLiquid suspension formulation QL expressed in ML over 90 days
    Provider actionBill liquid quantities in ML to align with the QL
    inv-199: MULTAQ TABLET QL example
    MULTAQ tablet QLQL(180 EA per 90 days)
    Formulary locationAntiarrhythmic entries list this 90-day EA QL
    Dispensing noteAdhere to the 90-day limit when authorizing refills
    inv-200: nebivolol hydrochloride tablet QL examples (10mg/20mg)
    Nebivolol 10mg QLQL(360 EA per 90 days)
    Nebivolol 20mg QLQL(180 EA per 90 days)
    Operational noteStrength-specific QLs for nebivolol listed in formulary — confirm strength when dispensing
    inv-201: nebivolol hydrochloride tablet QL example (20mg)
    Nebivolol 20mg QLQL(180 EA per 90 days)
    ContextLower EA QL compared with 10mg strength — follow formulary line for strength-specific limits
    Provider guidanceIndicate correct strength on claim to ensure QL is applied correctly
    inv-202: nisoldipine ER QL examples
    Nisoldipine ER QLsQL(180 EA per 90 days) or QL(90 EA per 90 days) depending on strength
    Formulary contextCalcium channel blocker ER formulations have strength-dependent QLs
    Provider noteConfirm strength-specific QL when prescribing nisoldipine ER
    inv-203: sacubitril/valsartan tablet QL example
    Sacubitril/valsartan QLQL(180 EA per 90 days)
    Formulary areaCardiovascular agents — ARNI class listing shows 90-day EA QL
    Provider guidanceApply 90-day limit for maintenance prescriptions to match formulary
    inv-204: ivabradine hydrochloride tablet QL example
    Ivabradine QLQL(180 EA per 90 days)
    Formulary noteListed in cardiovascular therapeutics with 90-day EA QL
    Operational noteUse formulary QL when authorizing chronic therapy refills
    inv-205: VYNDAMAX capsule QL example
    VYNDAMAX QLQL(31 EA per 31 days)
    AuthorizationPA accompanies VYNDAMAX listings — obtain PA and adhere to 31-day QL
    Provider actionSubmit PA with expected monthly quantity consistent with QL
    inv-206: ezetimibe QL example
    Ezetimibe QLQL(90 EA per 90 days)
    Formulary locationDyslipidemics section lists ezetimibe and combinations with 90-day EA QL
    Provider noteApply 90-day EA QL for maintenance dosing
    inv-207: fenofibrate products QL examples
    Fenofibrate product QLsQL(90 EA per 90 days) or QL(270 EA per 90 days) depending on formulation
    Formulary contextDifferent fenofibrate formulations have different QLs — check specific line
    Provider guidanceConfirm formulation and corresponding QL before authorizing larger supplies
    inv-208: rosuvastatin calcium tablet QL examples
    Rosuvastatin QLsQL(360 EA per 90 days) for 5/10mg; QL(90 EA per 90 days) for 40mg
    Formulary noteStatin strengths have differing 90-day EA QLs as listed
    Provider actionUse strength-specific QL when processing refills to avoid excess quantity
    inv-209: rosuvastatin 40mg QL example
    Rosuvastatin 40mg QLQL(90 EA per 90 days)
    ContextHigh-strength statin carries a smaller EA QL compared with lower strengths
    Operational tipConfirm strength to apply correct QL when authorizing therapy
    inv-210: PRALUENT INJECTION QL example
    PRALUENT injection QLQL(2 ML per 28 days)
    AuthorizationPA is listed with PRALUENT in Requirements/Limits — obtain PA before coverage
    Provider guidanceBill ML per 28 days for injection formulations to match QL
    inv-211: dapagliflozin (FARXIGA) QL example
    FARXIGA (dapagliflozin) QLQL(90 EA per 90 days)
    Formulary noteSGLT2 inhibitors list 90-day EA QLs; some entries include ST
    Provider actionConfirm step therapy (ST) where indicated in addition to QL compliance
    inv-212: VERQUVO tablet QL example
    VERQUVO tablet QLQL(30 EA per 30 days)
    AuthorizationPA accompanies VERQUVO entries in some lines — check Requirements/Limits
    Provider guidanceSubmit PA and monthly quantity consistent with the 30-day QL
    inv-213: tetrabenazine tablet QL example
    Tetrabenazine QLQL(248 EA per 31 days) for 12.5mg tablet
    AuthorizationPA accompanies some tetrabenazine entries — check Requirements/Limits
    Provider noteHigh EA QLs reflect chronic dosing schedules; align dispensing to QL
    inv-214: BETASERON INJECTION QL example
    BETASERON injection QLQL(14 EA per 28 days)
    Formulary contextMultiple sclerosis injectables list ML/EA QLs with PA flags
    Provider guidanceObtain PA and dispense per 28-day QL for coverage
    inv-215: methylphenidate solution QL example
    Methylphenidate solution QLQL(2700 ML per 90 days)
    Formulary noteLiquid ADHD formulations specify ML-based QLs in formulary
    Operational tipBill in ML and ensure 90-day aggregate does not exceed the QL
    inv-216: azelaic acid gel QL example
    Azelaic acid gel QL150 GM per 90 days
    Formulary locationAcne/rosacea topical agents list gram-based QLs
    Dispensing noteTotal grams per 90 days should not exceed listed QL for coverage
    inv-217: clobetasol propionate cream/gel QL example
    Clobetasol propionate cream/gel QL180 GM per 90 days
    Formulary contextMultiple clobetasol formulations list the same 90-day gram QL
    Provider actionTrack combined grams dispensed across formulations to remain within QL
    inv-218: calcipotriene & FILSUVEZ QL examples
    Calcipotriene products QLQL(360 GM per 90 days)
    FILSUVEZ gel QLQL(725.4 GM per 31 days)
    Provider noteDifferent topical products and gel formulations use GM-per-period QLs; confirm specific product line
    inv-219: FILSUVEZ GEL QL example
    FILSUVEZ GEL QLQL(725.4 GM per 31 days)
    Formulary noteLarge gram QL applied for FILSUVEZ gel with PA indicated
    Provider actionObtain PA and ensure dispensing quantity aligns with 31-day gram limit
    inv-220: OTEZLA XR QL example
    OTEZLA XR QLQL(31 EA per 31 days)
    AuthorizationPA accompanies OTEZLA XR in Requirements/Limits — obtain PA as required
    Provider notePrescribe monthly supply consistent with 31-day EA QL
    inv-221: ivermectin cream QL example
    Ivermectin cream QLQL(45 GM per 30 days)
    Formulary locationPediculicides/Scabicides section — gram-based QL with PA flag possible
    Provider guidanceBill gram-based quantity and adhere to 30-day limit for coverage
    inv-222: JYNARQUE/tolvaptan/XPHOZAH QL examples
    JYNARQUE therapy pack QLQL(56 EA per 28 days); PA indicated
    Tolvaptan QLsQL(31 EA per 31 days) for 15mg; QL(62 EA per 31 days) for 30mg; PA applies
    XPHOZAH QLQL(62 EA per 31 days); PA indicated
    inv-223: LOKELMA/VELTASSA/sevelamer QL examples
    LOKELMA/VELTASSA/Sevelamer packet QLsLOKELMA 5GM QL(270 EA per 90 days); LOKELMA 10GM QL(94 EA per 90 days); VELTASSA 8.4GM QL(270 EA per 90 days); VELTASSA 16.8/25.2GM QL(90 EA per 90 days); sevelamer carbonate packet 0.8gm QL(180 EA per 90 days); 2.4gm QL(270 EA per 90 days)
    Formulary sectionPhosphate binders and potassium binders list packet-based QLs
    Provider actionUse packet-level QLs when authorizing/delivering these binder therapies
    inv-232/233/234: LINZESS / lubiprostone / XIFAXAN QL examples
    LINZESS QLQL(90 EA per 90 days)
    Lubiprostone QLQL(180 EA per 90 days)
    XIFAXAN QLQL(93 EA per 31 days)
    inv-235: VOWST QL example
    VOWST QLQL(12 EA per 30 days)
    AuthorizationPA accompanies VOWST — obtain PA and adhere to monthly QL
    Provider noteVOWST (fecal microbiota product) has small monthly EA QL reflective of course dosing

    Abbreviations and Terms Used in the Formulary

    inv-103: Generic drugs definition
    Generic drug definitionA generic drug is FDA‑approved with the same active ingredient as the brand‑name drug and generally costs less
    SubstitutionGeneric drugs usually can be substituted for the brand‑name at the pharmacy without a new prescription depending on state law
    Formulary noteFormulary covers both brand‑name and generic drugs; check formulary listings for specific coverage
    inv-104: Biological products / Biosimilars definition
    Biological products / BiosimilarsBiological products are more complex than typical drugs and have biosimilar alternatives rather than traditional generics; some biosimilars may be interchangeable depending on state law
    SubstitutionInterchangeable biosimilars may be substituted for the original biological product per state law
    ReferenceSee Evidence of Coverage for details about biological product substitutions
    inv-105: PA definition
    PA definitionPA = Prior Authorization: plan requires approval before filling the prescription
    Operational effectIf approval is not obtained, the plan may not cover the drug
    Where shownPA appears in the Requirements/Limits column of formulary entries
    inv-106: QL definition
    QL definitionQL = Quantity Limit: plan limits the amount of the drug that will be covered over a specified time period
    Format examplesShown as QL(number EA per days) or QL(number ML per days) in Requirements/Limits
    Clinical implicationDispensed quantity must conform to listed QL to be covered
    inv-107: ST definition
    ST definitionST = Step Therapy: plan may require trying a specified drug first before covering another drug for the same condition
    ProcessIf the preferred drug fails, the plan will then cover the alternative drug
    Where shownST flag appears in Requirements/Limits for select products (e.g., oxcarbazepine ER)
    inv-108: OVM definition
    OVM definitionOVM = Oncology Value Management: prior authorization program for antineoplastics and oncology supportive care drugs administered by OncoHealth
    RequirementPhysician must submit additional information for B/D determination and OVM reviews
    ImplicationClaims for agents with 'OVM' may require submission through OncoHealth prior to coverage
    inv-109: NDS definition
    NDS definitionNDS = Non-Extended Day Supply: certain controlled or limited‑supply drugs are limited to shorter fills (e.g., 30–31 days)
    ApplicationMany opioid analgesics and benzodiazepines carry NDS flags in the formulary
    Provider noteUse NDS when submitting days supply for affected controlled substances
    inv-110: QL / PA / NDS abbreviations noted
    Abbreviation mappingQL = Quantity Limit; PA = Prior Authorization; NDS = Non-Extended Day Supply; ST = Step Therapy; OVM = Oncology Value Management
    Where usedThese abbreviations appear in the Requirements/Limits column of formulary table entries
    ActionFollow the Requirements/Limits annotations when prescribing or submitting claims/PA requests
    inv-111: QL exact values for specific products (definition example)
    QL exact-value exampleDIFICID suspension QL(136 ML per 10 days) — example of exact QL value in formulary
    UseDemonstrates how QLs can specify ML per a short treatment timeframe for certain antibiotics
    Provider noteAlign dispensing with short-course QLs for appropriate coverage (e.g., 10-day courses)
    inv-112: PA shown as requirement in Requirements/Limits
    PA as requirement in tableThe formulary introduction explains Prior Authorization is required for certain drugs and appears in the Requirements/Limits column
    ImplicationClaims without required PA may be denied
    Where to checkSee Requirements/Limits field for PA flags on each product line
    inv-113: ST example (oxcarbazepine er)
    ST exampleoxcarbazepine ER formulation lists 'ST' in Requirements/Limits indicating a step therapy requirement
    Formulary locationSodium Channel Agents / Anticonvulsant sections
    Provider actionFollow step therapy rules when initiating oxcarbazepine ER to obtain coverage
    inv-114: NDS used for rescue/acute products examples
    NDS / acute/rescue examplesNDS used for rescue/acute products (examples in document: Nayzilam, diazepam gel, Libervant, Valtoсo) — indicates non-extended day supply limits
    Formulary implicationNDS flags restrict maximum days supply at retail/mail fill (commonly 30–31 days)
    Provider guidanceWhen prescribing rescue agents, account for NDS in days supply and quantity to ensure coverage
    inv-115: PA definition (redundant entry)
    PA definition (redundant)Prior Authorization: plan requires approval before filling the prescription (appears in Requirements/Limits)
    Operational impactClaims submitted without required PA may be denied
    Where to findIntroduction and Requirements/Limits fields in the formulary document
    inv-116: QL definition (redundant entry)
    QL definition (redundant)Quantity Limit — maximum quantity permitted within a specified time frame as listed (format QL(number EA/ML per days))
    UsageUsed throughout the formulary to control covered drug quantities
    Provider actionEnsure dispensing quantities and days supply conform to QL
    inv-117: ST definition (redundant entry)
    ST definition (redundant)Step Therapy — requires trying specified alternative drug(s) before covering listed drug
    Formulary examplesOxcarbazepine ER and EXXUA entries show ST flags
    Provider guidanceComply with ST flags when initiating therapy to secure coverage
    inv-118: QL example (Requirements/Limits)
    Topical QL exampleKLAYS/nyamyc etc. show QL(180 GM per 90 days) as topical powder/cream examples
    Formulary contextTopical and powder products commonly use gram-based QLs
    Provider noteAggregate grams across topical products when confirming covered quantity
    inv-119: PA example (Requirements/Limits)
    PA example (Requirements/Limits)Several anticonvulsant entries show 'PA' in Requirements/Limits indicating prior authorization is required (e.g., EPIDIOLEX, brivaracetam entries)
    Provider actionSubmit PA with clinical justification for listed anticonvulsant products to obtain coverage
    Formulary noteCheck product line for both QL and PA flags — both may apply
    inv-120: ST example (Requirements/Limits)
    ST example in Requirements/LimitsOxcarbazepine ER line shows 'ST' indicating step therapy requirement
    ImpactCoverage may be denied if step therapy requirements are unmet
    Provider guidanceDocument prior trial of preferred agent when submitting PA if ST applies

    Background Information

    Biological products are complex medicines derived from living organisms and are not interchangeable with small‑molecule generics in the same way as chemical drugs. The formulary distinguishes original biological products and their biosimilar alternatives; some biosimilars may be designated as interchangeable and substituted per applicable state law. For more information on biosimilars and substitution, see the formulary introduction and the plan’s guidance on biosimilar preferences and exceptions.